Shares of Cellectis SA (NASDAQ:CLLS) shot up 2.7% on Monday . The company traded as high as $27.00 and last traded at $26.59, with a volume of 64,684 shares changing hands. The stock had previously closed at $25.90.

A number of equities analysts have recently commented on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Cellectis SA in a report on Friday, August 5th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Cellectis SA in a report on Wednesday, July 27th. Zacks Investment Research downgraded shares of Cellectis SA from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Cellectis SA in a report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $43.60.

The stock’s market capitalization is $938.83 million. The stock has a 50 day moving average price of $26.53 and a 200 day moving average price of $27.02.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.